Vaxxinity Inc
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial … Read more
Vaxxinity Inc (VAXX) - Total Liabilities
Latest total liabilities as of March 2024: $30.90 Million USD
Based on the latest financial reports, Vaxxinity Inc (VAXX) has total liabilities worth $30.90 Million USD as of March 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Vaxxinity Inc - Total Liabilities Trend (2019–2023)
This chart illustrates how Vaxxinity Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Vaxxinity Inc Competitors by Total Liabilities
The table below lists competitors of Vaxxinity Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tomer Energy Royalties 2012 Ltd
TA:TOEN
|
Israel | ILA261.44 Million |
|
ELIA SYSTEM OP. (E4S.SG)
STU:E4S
|
Germany | €13.87 Billion |
|
Knusford Bhd
KLSE:5035
|
Malaysia | RM156.80 Million |
|
ESGL Holdings Limited Warrants
NASDAQ:ESGLW
|
USA | $11.14 Million |
|
EXXON MOBIL - Dusseldorf Stock Exchang
DU:XONA
|
Germany | €185.52 Billion |
|
Ucommune International Ltd
NASDAQ:UK
|
USA | $173.94 Million |
|
Valora Effekten Handel AG
F:VEH
|
Germany | €674.97K |
Liability Composition Analysis (2019–2023)
This chart breaks down Vaxxinity Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.70 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vaxxinity Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vaxxinity Inc (2019–2023)
The table below shows the annual total liabilities of Vaxxinity Inc from 2019 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $30.90 Million | -30.12% |
| 2022-12-31 | $44.22 Million | +16.21% |
| 2021-12-31 | $38.05 Million | -72.33% |
| 2020-12-31 | $137.52 Million | +174.44% |
| 2019-12-31 | $50.11 Million | -- |